[CAR-T therapy significantly reduces the symptoms of severe rheumatoid arthritis] September 1st, Chimeric Antigen Receptor T-cell immunotherapy (CAR-T) is mainly used to treat cancer, but this type of personalized therapy prepared from the patient's own immune cells is also expected to be used for autoimmune diseases. German scientists reported the results of the world's first relevant clinical trial: After receiving CAR-T treatment, the symptoms of six patients with severe rheumatoid arthritis were significantly reduced, and three of them no longer needed any anti-rheumatic drugs at the end of the observation period. The relevant paper was published in the latest issue of Nature Medicine.